文献速递糖尿病

β细胞在2型糖尿病中的作用:近5年新发现

The role of the beta cell in type 2 diabetes: new findings from the last 5 years.
PubMed 文献 · Diabetologia · 2025-08-06

本文综述近5年以人类研究为主的2型糖尿病起始、进展与缓解方面的关键进展。多组学等技术提示早期胰岛素分泌异常而非β细胞质量减少在早期2型糖尿病发病中起根本和主要作用;减重及靶向肠促胰素系统的新药可实现糖尿病缓解。

要点

  • 早期2型糖尿病以胰岛素分泌异常为主,而非β细胞质量减少。
  • β细胞为异质性群体,对应激反应不同,性别差异不可低估。
  • 减重与靶向肠促胰素系统的新药已被临床试验证明可实现糖尿病缓解。

核心结论

  • 早期胰岛素分泌异常而非β细胞质量减少在早期2型糖尿病发病中起根本和主要作用。
  • 糖尿病缓解可通过降糖治疗实现,尤其是以减重为核心的治疗策略。
  • β细胞是异质性群体,对应激反应不同,性别相关差异不应被低估。

研究设计与样本

  • 综述类文章,聚焦近5年发表、以人类研究为主的文献。
  • 涵盖全基因组方法、离体人胰岛研究及大型临床试验中新型肠促胰素药物的评估。

主要发现

  • 多组学技术将2型糖尿病风险变异与胰岛内分泌细胞的基因调控网络联系起来。
  • 这些网络控制β细胞发育、功能与应激耐受。
  • 来自其他胰岛细胞、外分泌胰腺、肠道和胰岛素敏感组织的致病信号参与内在β细胞缺陷。
  • 临床试验显示减重策略(含减重手术)及靶向肠促胰素系统的新药可实现糖尿病缓解。

临床怎么用

  • 关注早期胰岛素分泌异常作为2型糖尿病早期发病的核心环节。
  • 重视β细胞异质性与性别差异对治疗反应的影响。
  • 将减重及靶向肠促胰素系统的策略作为实现糖尿病缓解的重要方向。

局限性

  • 作者指出,仍需更多研究才能将这些进展转化为临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in genome-wide approaches, the availability of isolated human islets for research and the evaluation of novel incretin mimetics in large clinical trials have brought about remarkable progress in our understanding of the role of the pancreatic beta cell in type 2 diabetes. Here, we review key developments in type 2 diabetes initiation, progression and remission, focusing mostly on human studies published in the last 5 years. Progress in multi-omics technologies has enabled researchers to identify links between type 2 diabetes risk variants and gene regulatory networks in islet endocrine cells that control beta cell development, function and stress resilience. These studies support the notion that early abnormalities in insulin secretion, rather than a reduction in beta cell mass, play a fundamental and primary role in early type 2 diabetes pathogenesis. Contributing to these intrinsic beta cell defects are various pathogenic signals from other (endocrine and non-endocrine) islet cells, the exocrine pancreas, the gut and insulin-sensitive tissues. It has also become apparent that beta cells comprise a heterogeneous population that responds differently to stress situations and that sex-related differences in beta cell responses should not be underestimated. Finally, human clinical trials have clearly demonstrated that diabetes remission can be achieved using glucose-lowering therapies and particularly strategies focused on weight loss, including bariatric surgery and, more recently, the use of highly efficient new drugs targeting the incretin system. While progress in the last 5 years has been significant, much remains to be uncovered to bring these advances to the clinic and thereby alleviate the dramatic consequences of type 2 diabetes complications for the hundreds of millions of people who live with this disease.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Yau B, Ghislain J, Kebede MA, et al. The role of the beta cell in type 2 diabetes: new findings from the last 5 years. Diabetologia. 2025. PMID: 40768044. doi:10.1007/s00125-025-06499-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。